You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》昭衍新药(06127.HK)公开发售超购309倍及上限定价 一手中签率仅5%
阿思达克 02-25 08:58
昭衍新药(06127.HK)公布招股结果,发售价定於151元,为上限定价(招股价介乎133元至151元),公开发售录超购309倍,经重新分配後,公开发售股数增至36%。每手100股,中签率为5%。该股将於明日(26日)上市。中信证券为独家保荐人。

公司为上市引入11名基石投资者,包括Lake Bleu Prime、Orbimed基金、中国结构调整基金及CPE Fund等,合共认购1,375.98万股股份,相当於紧随全球发售完成後公司已发行股本约5.1%。

公司预计集资所得款项净额约为62.86亿元,当中16%将用於提高集团苏州设施的服务能力;10%将用於增强集团美国业务以迎合客户日益增长的对Biomere所提供服务的需求;39%将用於在广州及重庆建设新设施;5%将用於拓展及深化集团综合合同研究组织服务;20%将用於拓宽药物研发价值链上的综合服务范围并拓展海外布局的策略;以及10%为营运资金及一般企业用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account